The results demonstrated that the nucleolin–TopIIA interaction prevents the killing effects of TopIIA targeting agents on DLBCL cells by facilitating DNA damage repair instead of cleavage. Here, NUCLEOLIN is linked to diffuse large B-cell lymphoma.